MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
On Tuesday, MAIA Biotechnology Inc (NASDAQ:MAIA) announced treatment updates from its Phase 2 THIO-101 trial of THIO sequenced with Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) cemiplimab (Libtayo) for advanced non-small-cell-lung-cancer patients who failed two or more standard-of-care therapy regimens.
MAIA生物技术公司（纳斯达克股票代码：MAIA）在周二公布了从其第二期THIO-101试验的治疗更新中获得的消息，该试验将THIO与再生元制药公司（纳斯达克股票代码：REGN）的Cemiplimab（Libtayo）用于治疗晚期非小细胞肺癌患者，其治疗失败了两个或更多的标准疗法方案。
The trial's therapeutic regimen is cycled every three weeks, with THIO 180mg administered in 60mg incremental doses on days 1, 2 and 3, followed by immune activation on day 4 (no dosing), and cemiplimab 350mg administered on day 5.
该试验的治疗方案每三周循环一次，在第1、2和3天分3次口服THIO 180mg，第4天进行免疫激活（不用药物），第5天注射Cemiplimab 350mg。
As of the latest clinical cutoff date, June 12, 2024:
截至2024年6月12日最新的临床截止日期，仍有6名患者在治疗中，在接受至少12个月的治疗后。
- Six patients remain on treatment following at least 12 months of therapy.
- Treatment with THIO followed by cemiplimab has been well tolerated throughout the trial, with much lower toxicity than standard-of-care treatments.
- Continuing treatment past 12 months demonstrates safety, efficacy and ongoing benefit from MAIA's novel telomere targeting NSCLC therapy.
- 在至少接受12个月治疗后，有6名患者仍在接受治疗。
- 与标准治疗相比，THIO后随Cemiplimab的治疗在整个试验期间都很耐受，毒副反应明显降低。
- 延续治疗超过12个月，可以证明MAIA的新型端粒靶向NSCLC疗法有安全性、疗效和持续的好处。
"Our longest treated patient so far has completed 21 cycles of THIO sequenced with a CPI, and six patients who have crossed the 12-month survival follow-up are continuing the treatment," said Vlad Vitoc, chairman and chief executive officer of MAIA.
MAIA的董事长兼首席执行官Vlad Vitoc表示：“到目前为止，我们最长治疗的患者完成了THIO和CPI 21个疗程的顺序治疗，六名已经接受了12个月以上的随访，继续治疗。”
In June, MAIA Biotechnology shared new efficacy data from its Phase 2 THIO-101 study of THIO.
今年6月，MAIA生物技术公司分享了THIO-101第二期研究的新的疗效数据。
Updated results show a favorable overall response rate (ORR) of 38% and a disease control rate (DCR) of 85% from THIO + CPI in third-line treatment:
更新后的结果显示，第三线治疗中THIO + CPI显示出38%的相对疗效率（ORR）和85%的疾病控制率（DCR）：
- The disease control rate (DCR) was 85% for THIO vs. standard of care DCR of 25–35% for chemotherapy.
- 65% of patients crossed the 5.8-month overall survival (OS) threshold.
- 85% of patients crossed the 2.5-month progression-free survival (PFS) threshold.
- Median survival follow-up time is currently 9.1 months (n=20)
- THIO的疾病控制率（DCR）为85%，化疗的标准疾病控制率（DCR）为25-35%。
- 65%的患者跨越了5.8个月的总生存期（OS）门槛。
- 85%的患者跨越了2.5个月的无进展生存期（PFS）门槛。
- 目前的中位生存期为9.1个月（n=20）。
Price Action: MAIA stock is down 14.25% at $3.31 at last check Tuesday.
价格变动：截至上周二的最后查看，MAIA股票下跌了14.25%，至3.31美元。
- Axsome Therapeutics' CNS Portfolio Poised for Major Growth – Analyst Predicts Strong Future.
- Axsome Therapeutics的CNS组合前景看好-分析师预测未来强劲。
Image created using artificial intelligence via Midjourney.
图像由Midjourney通过人工智能创建。